APO RESEARCH · REPORT
Human Microbiome
The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
Product & engineering
Understand the product.
The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
Selected research
Industry Growth & Trends
Global Human Microbiome Industry Growth and Trends Forecast to 2032
Market perspective
The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
Read the full market overview
According to APO Research, the global Human Microbiome market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Report Scope
This report provides a structured, data-driven view of the global Human Microbiome market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Human Microbiome market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Human Microbiome market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Human Microbiome.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Human Microbiome market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Human Microbiome Market by Company
Vedanta
Seres Therapeutics
Second Genome
Rebiotix
ActoGeniX
Enterome BioScience
AvidBiotics
4D Pharma Research Ltd
Enterologics
Metabogen
Metabiomics
Ritter Pharmaceuticals
Osel
Symberix
Miomics
Symbiotix Biotherapies
MicroBiome Therapeutics LLC
Human Microbiome Segment by Type
Gastrointestinal Tract Human Micobiome
Urogenital Tract Human Micobiome
Others
Human Microbiome Segment by Application
Treatment
Diagnosis
Human Microbiome Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Microbiome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Microbiome and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Microbiome.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Human Microbiome companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Gastrointestinal Tract Human Micobiome
- Urogenital Tract Human Micobiome
- Others
Applications
- Treatment
- Diagnosis
Companies covered
- Vedanta
- Seres Therapeutics
- Second Genome
- Rebiotix
- ActoGeniX
- Enterome BioScience
- AvidBiotics
- 4D Pharma Research Ltd
- Enterologics
- Metabogen
- Metabiomics
- Ritter Pharmaceuticals
- Osel
- Symberix
- Miomics
- Symbiotix Biotherapies
- MicroBiome Therapeutics LLC
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Human Microbiome Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Human Microbiome Market Size by Region (2021-2032)
- 1.4.1 Global Human Microbiome Market Size by Region (2021-2026)
- 1.4.2 Global Human Microbiome Market Size by Region (2027-2032)
- 1.5 Key Regions Human Microbiome Market Size (2021-2032)
- 1.5.1 North America Human Microbiome Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Human Microbiome Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Human Microbiome Market Size Growth Rate (2021-2032)
- 1.5.4 South America Human Microbiome Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Human Microbiome Market Size Growth Rate (2021-2032)
2 Human Microbiome Market by Type
- 2.1 Type Introduction
- 2.1.1 Gastrointestinal Tract Human Micobiome
- 2.1.2 Urogenital Tract Human Micobiome
- 2.1.3 Others
- 2.2 Global Human Microbiome Market Size by Type
- 2.2.1 Global Human Microbiome Market Size Overview by Type (2021-2032)
- 2.2.2 Global Human Microbiome Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Human Microbiome Market Size Forecasted by Type (2027-2032)
- 2.3 Global Human Microbiome Market Size by Regions
- 2.3.1 North America Human Microbiome Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Human Microbiome Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Human Microbiome Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Human Microbiome Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Human Microbiome Market Size Breakdown by Type (2021-2026)
3 Human Microbiome Market by Application
- 3.1 Type Introduction
- 3.1.1 Treatment
- 3.1.2 Diagnosis
- 3.2 Global Human Microbiome Market Size by Application
- 3.2.1 Global Human Microbiome Market Size Overview by Application (2021-2032)
- 3.2.2 Global Human Microbiome Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Human Microbiome Market Size Forecasted by Application (2027-2032)
- 3.3 Global Human Microbiome Market Size by Regions
- 3.3.1 North America Human Microbiome Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Human Microbiome Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Human Microbiome Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Human Microbiome Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Human Microbiome Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Human Microbiome Industry Trends
- 4.2 Human Microbiome Industry Drivers
- 4.3 Human Microbiome Industry Opportunities and Challenges
- 4.4 Human Microbiome Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Human Microbiome Revenue (2021-2026)
- 5.2 Global Human Microbiome Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Human Microbiome Key Company Headquarters & Area Served
- 5.4 Global Human Microbiome Company, Product Type & Application
- 5.5 Global Human Microbiome Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Human Microbiome Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Human Microbiome Players Market Share by Revenue in 2025
- 5.6.3 2025 Human Microbiome Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Vedanta
- 6.1.1 Vedanta Company Information
- 6.1.2 Vedanta Business Overview
- 6.1.3 Vedanta Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Vedanta Human Microbiome Product Portfolio
- 6.1.5 Vedanta Recent Developments
- 6.2 Seres Therapeutics
- 6.2.1 Seres Therapeutics Company Information
- 6.2.2 Seres Therapeutics Business Overview
- 6.2.3 Seres Therapeutics Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Seres Therapeutics Human Microbiome Product Portfolio
- 6.2.5 Seres Therapeutics Recent Developments
- 6.3 Second Genome
- 6.3.1 Second Genome Company Information
- 6.3.2 Second Genome Business Overview
- 6.3.3 Second Genome Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Second Genome Human Microbiome Product Portfolio
- 6.3.5 Second Genome Recent Developments
- 6.4 Rebiotix
- 6.4.1 Rebiotix Company Information
- 6.4.2 Rebiotix Business Overview
- 6.4.3 Rebiotix Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Rebiotix Human Microbiome Product Portfolio
- 6.4.5 Rebiotix Recent Developments
- 6.5 ActoGeniX
- 6.5.1 ActoGeniX Company Information
- 6.5.2 ActoGeniX Business Overview
- 6.5.3 ActoGeniX Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 ActoGeniX Human Microbiome Product Portfolio
- 6.5.5 ActoGeniX Recent Developments
- 6.6 Enterome BioScience
- 6.6.1 Enterome BioScience Company Information
- 6.6.2 Enterome BioScience Business Overview
- 6.6.3 Enterome BioScience Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Enterome BioScience Human Microbiome Product Portfolio
- 6.6.5 Enterome BioScience Recent Developments
- 6.7 AvidBiotics
- 6.7.1 AvidBiotics Company Information
- 6.7.2 AvidBiotics Business Overview
- 6.7.3 AvidBiotics Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 AvidBiotics Human Microbiome Product Portfolio
- 6.7.5 AvidBiotics Recent Developments
- 6.8 4D Pharma Research Ltd
- 6.8.1 4D Pharma Research Ltd Company Information
- 6.8.2 4D Pharma Research Ltd Business Overview
- 6.8.3 4D Pharma Research Ltd Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 4D Pharma Research Ltd Human Microbiome Product Portfolio
- 6.8.5 4D Pharma Research Ltd Recent Developments
- 6.9 Enterologics
- 6.9.1 Enterologics Company Information
- 6.9.2 Enterologics Business Overview
- 6.9.3 Enterologics Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Enterologics Human Microbiome Product Portfolio
- 6.9.5 Enterologics Recent Developments
- 6.10 Metabogen
- 6.10.1 Metabogen Company Information
- 6.10.2 Metabogen Business Overview
- 6.10.3 Metabogen Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Metabogen Human Microbiome Product Portfolio
- 6.10.5 Metabogen Recent Developments
- 6.11 Metabiomics
- 6.11.1 Metabiomics Company Information
- 6.11.2 Metabiomics Business Overview
- 6.11.3 Metabiomics Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Metabiomics Human Microbiome Product Portfolio
- 6.11.5 Metabiomics Recent Developments
- 6.12 Ritter Pharmaceuticals
- 6.12.1 Ritter Pharmaceuticals Company Information
- 6.12.2 Ritter Pharmaceuticals Business Overview
- 6.12.3 Ritter Pharmaceuticals Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Ritter Pharmaceuticals Human Microbiome Product Portfolio
- 6.12.5 Ritter Pharmaceuticals Recent Developments
- 6.13 Osel
- 6.13.1 Osel Company Information
- 6.13.2 Osel Business Overview
- 6.13.3 Osel Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Osel Human Microbiome Product Portfolio
- 6.13.5 Osel Recent Developments
- 6.14 Symberix
- 6.14.1 Symberix Company Information
- 6.14.2 Symberix Business Overview
- 6.14.3 Symberix Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Symberix Human Microbiome Product Portfolio
- 6.14.5 Symberix Recent Developments
- 6.15 Miomics
- 6.15.1 Miomics Company Information
- 6.15.2 Miomics Business Overview
- 6.15.3 Miomics Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Miomics Human Microbiome Product Portfolio
- 6.15.5 Miomics Recent Developments
- 6.16 Symbiotix Biotherapies
- 6.16.1 Symbiotix Biotherapies Company Information
- 6.16.2 Symbiotix Biotherapies Business Overview
- 6.16.3 Symbiotix Biotherapies Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.16.4 Symbiotix Biotherapies Human Microbiome Product Portfolio
- 6.16.5 Symbiotix Biotherapies Recent Developments
- 6.17 MicroBiome Therapeutics LLC
- 6.17.1 MicroBiome Therapeutics LLC Company Information
- 6.17.2 MicroBiome Therapeutics LLC Business Overview
- 6.17.3 MicroBiome Therapeutics LLC Human Microbiome Revenue, Global Share and Gross Margin (2021-2026)
- 6.17.4 MicroBiome Therapeutics LLC Human Microbiome Product Portfolio
- 6.17.5 MicroBiome Therapeutics LLC Recent Developments
7 North America
- 7.1 North America Human Microbiome Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Human Microbiome Market Size by Country (2021-2026)
- 7.3 North America Human Microbiome Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Human Microbiome Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Human Microbiome Market Size by Country (2021-2026)
- 8.3 Europe Human Microbiome Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Human Microbiome Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Human Microbiome Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Human Microbiome Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Human Microbiome Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Human Microbiome Market Size by Country (2021-2026)
- 10.3 South America Human Microbiome Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Human Microbiome Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Human Microbiome Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Human Microbiome Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst